The Patent Finder

Yungjin Pharm. Co., Ltd.

Also on record
Records under this name other than the patents Yungjin Pharm. Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.

Showing 1 to 10 of 10 · Back to Yungjin Pharm. Co., Ltd.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,969,653Extracellular Vesicles Derived from Gram-Positive Bacteria, and Use Thereof
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 10,927,0851,2-naphthoquinone based derivative and method of preparing the same
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 9,066,922Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
Term ended
Term ended Feb 15, 2026 · USPTO record
Term endedTerm ended Feb 15, 2026USPTO record
US 9,273,359Extracellular vesicles derived from Gram-positive bacteria, and use thereof
Formerly held
Lapsed on the fee record
Ended Mar 1, 2024 · USPTO record
Lapsed on the fee recordEnded Mar 1, 2024USPTO record
US 9,180,101Pharmaceutical composition simultaneously having rapid-acting property and long-acting property
Lapsed on the fee record
Ended Nov 10, 2023 · USPTO record
Lapsed on the fee recordEnded Nov 10, 2023USPTO record
US 8,029,832Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
Lapsed on the fee record
Ended Oct 4, 2023 · USPTO record
Lapsed on the fee recordEnded Oct 4, 2023USPTO record
US 8,466,141Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
Lapsed on the fee record
Ended Jun 18, 2021 · USPTO record
Lapsed on the fee recordEnded Jun 18, 2021USPTO record
US 8,404,869Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome
Lapsed on the fee record
Ended Mar 26, 2021 · USPTO record
Lapsed on the fee recordEnded Mar 26, 2021USPTO record
US 7,375,243Method for preparation of amino acid chelate
Lapsed on the fee record
Ended May 20, 2020 · USPTO record
Lapsed on the fee recordEnded May 20, 2020USPTO record
US 7,901,716Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng
Lapsed on the fee record
Ended Mar 8, 2019 · USPTO record
Lapsed on the fee recordEnded Mar 8, 2019USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited